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ABSTRACT 
 
A simple, precise, accurate RP-HPLC method has been developed and validated for the 
analysis and stability studies of Norfloxacin (NOR) and Loperamide (LOP) in combined 
dosage form. The chromatographic separation and quantization of NOR and LOP in 
HPLC was achieved on a Phenomenex C-18(250 x 4.6 mm 5 µm) column using the 
mobile phase in isocratic mode constituting of eluent ACN: Water: H3PO4 (pH adjusted 
to 4.5 with triethylamine) in the ratio 50:50:0.2 v/v/v at a flow rate of 1 ml/min. Eluted 
components were detected at 222 nm. The method showed high sensitivity and good 
linearity over the concentration range of 5 to 25 µg/ml, Y=32737 x – 4790, Y=24054 x + 
3766 and the correlation coefficient R
2
 was found to be 0.9998, 0.9995 for NOR and LOP 
respectively. The retention time was found to be 2.09 for NOR and 4.51 for LOP. The 
method validation was carried out as per ICH guidelines. The LOD and LOQ were found 
to be 1.17 µg/ml and 3.59 µg/ml for NOR and 0.16 µg/ml and 0.39 µg/ml for LOP 
respectively. The mean recovery values for NOR and LOP was found to be in the range 
of 99.46 – 100.76 %. The method was specific and no interference was observed when 
the drugs were estimated in presence of excipients. The method was validated for 
linearity, range, precision, accuracy, ruggedness and robustness. After the validation the 
method was successfully applied for the estimation of norfloxacin and loperamide in 
combined dosage form. 
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CHAPTER 1 
INTRODUCTION 
As the mankind made his way through remote times and places, he was always 
followed by disease and sickness from ill health. Market is filled with combination of 
drugs in various dosage forms. The multi-component formulations are so much 
important nowadays due to greater patient acceptability, increased potency, multiple 
action, fewer side effects and quicker relief. 
 
Analytical chemistry is the science of making quantitative measurements. In practice, 
quantifying analytes in a complex sample becomes an exercise in problem solving. 
 
To meet these needs, analytical chemistry courses usually emphasize equilibrium, 
spectroscopic and electrochemical analysis, separations and statistics. Analytical 
chemistry requires broad background knowledge of chemical and physical concepts. 
These hypermedia documents contain links to the fundamental principles that 
underlay the different analytical methods. A fundamental understanding makes it 
easier to identify when a particular problem cannot be solved by traditional methods, 
and gives an analyst the knowledge that is needed to develop creative approaches or 
new analytical methods
1
. 
 
 General analytical techniques:
 2-3 
The main techniques used for quantitative analysis are based upon: 
1) Appropriate chemical reaction based the amount of reagent required for the 
entire reactions and the total quantity of product obtained. 
2) Suitable electrical measurements, involves the measurement of current, 
voltage or resistance as a measure to the concentration of a certain analyte 
present. 
3) The measurement of  optical properties which depends either on measurement 
of the radiant energy absorbed or the emission of radiant energy of a 
particular wavelength by the sample. 
4) In the area of pharmaceutical science and technology instrumental analysis 
have become an important mean of quantitative and qualitative estimation. 
Due to the greater sensitivity, speed of analysis, low detection limit, ability 
for simultaneous determination and programmed operational availability of 
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the instruments as compared with the other method of analysis have shows its 
prevalence. Most commonly used instrumental methods are Chromatography, 
Ultra violet spectroscopy, Infra red spectroscopy, X-ray methods etc. 
5) Radioactivity is the measurement of concentration of the radiation from a 
naturally radioactive substances or an induced radioactive substance produced 
from the exposure of the test compound to a neutral source. 
6) In case of thermal methods alteration in weight or alteration in power, 
calculated as a function of temperature is considered. Different types of 
thermal methods commonly used are thermo gravimetry, differential scanning 
calorimetry etc. 
From all the methods mention above for the analysis of pharmaceutical 
chromatography has improved a lot for both the quantitative and qualitative analysis. 
Different types of chromatographic methods are available. 
 
 
Chromatographic methods: 
 Gas chromatography (GC). 
 High performance liquid chromatography (HPLC). 
 Liquid chromatography-mass spectroscopy (LC-MS). 
 Gas chromatography –mass spectroscopy (GC-MS). 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHHY: 
High Performance Liquid Chromatography (HPLC) is a type of chromatography 
which is predominantly used analytical techniques. Chromatographic method is a 
separation technique which involves movement of analyte between the stationary 
phase and mobile phase. 
 
Instrumentation HPLC system: 
4 
HPLC instrumentation includes a 
 Mobile phase reservoir 
 Pump 
 Injector  
 Column 
 Detector  
 Data system.  
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Fig 1. Schematic representation of HPLC instrument 
Mobile phase reservoir: 
The commonly used solvent reservoir is a glass bottle. Most of the manufacturers 
provide bottles with special caps. For connection of this mobile phase reservoir to the 
pump inlet Teflon tubing and filters are used.  
 
Pump:  
High pressure pumps are needed to force solvents through packed stationary phase 
beds. Smaller bed particles require higher pressure. There are many advantages to 
using smaller particles, but they are not essential for all separations. The advantages 
are higher resolution, faster analyses, and increased sample load capacity. 
 
Injector:   
Sample can be introduced in various ways. The simplest method is to use an injection 
valve. In more sophisticated LC systems, automatic sampling devices are incorporated 
where the sample is introduced with the help of auto samplers and microprocessors. 
 
Column:   
HPLC columns are 5, 10, 15 and 25 cm in length and are filled with small diameter 
(3, 5 or 10 µm) particles. The internal diameter of the columns is usually 4.6 mm. 
Introduction  
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This is considered the best compromise for sample capacity, mobile phase 
consumption, speed and resolution. 
 
Detector:   
When a substance has passed through the column there are several ways to detect it. A 
common method which is easy to explain is ultra-violet absorption. The amount of 
light absorbed will depend on the amount of a particular compound that passes 
through the beam at the time.
5 
 
Data system:   
 Modern data collection techniques can aid the signal analysis since the detector 
signal is electronic. In addition, some systems can store data in a retrievable form for 
highly sophisticated computer analysis at a later time.  The main goal in using 
electronic data systems is to increase analysis accuracy and precision, while reducing 
operator attention. 
 
ADVANTAGES OF HPLC: 
6 
1. Wide variety of packing materials allows the separation of most chemical 
species. The phases that are most extensively used for drug substances of low 
molecular weight (less than 1000) and their decomposition products or 
metabolites are the adsorption systems based on silica and the reversed –phase 
systems based on octyl silyl or octa decyl silyl bonded on silica. 
2. The different types of detectors available permit the sensitive detection of most 
chemical type, and the accuracy and precision with which eluted substances may 
be quantified. 
3. Micro particulate packing materials give excellent separation of similar 
substances. 
4. The number of theoretical plates given by a standard analytical column is of the 
order of 5000-10000 and this gives adequate resolution of the vast majority of 
mixtures which are likely to require separation. 
5.  A combination of HPLC and spectrometric techniques allows the simultaneous 
quantization and identification of solutes as they elute from the column. 
6. In the pharmaceutical industry, it is essential to produce pure drug substances, 
suitable for human consumption for in a cost effective manner. The purity of 
drug substance can be checked by separation techniques such a GC, TLC, 
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HPLC. These techniques tends to be more sensitive and specific than 
spectroscopic method.
7 
 
7. HPLC has an advantage over GC as an analytical technique, since analytes need 
be neither volatile nor extremely stable to elevent temperatures. Highly accurate, 
almost universal detectors, makes quantification easier than with TLC. 
8. Standardization either by external or internal standard techniques made it 
possible to convert for  structurally depended differences in detector  response.
8
  
 
ANALYTICAL METHOD DEVELOPMENT: 
Analytical method development plays an important role in the discovery, 
development and manufacture of pharmaceuticals. The official test methods that 
results from these process are used by quality control laboratories to ensure that 
results from these process are used by quality control laboratories to ensure the 
identity, potency, purity and performance of drug products.
9
 To ensure compliance 
with quality and safety standards USA, Europe, Japan, and other countries have 
published their own pharmacopeia’s.  
 
Analytical Method Development by HPLC: 
High performance liquid chromatography (HPLC) is widely used technique in various 
industries such as pharmaceuticals, nutraceutical, cosmeceutical, oleochemical, 
biotechnological, food and beverage industries. HPLC is uded to analyze raw 
materials and products during formulation and quality control assurance stages. In 
HPLC the separation is based on interaction and differential partition of the sample 
between the mobile pahse and stationary phase
10. 
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Modes of HPLC: 
There are five modes in HPLC
 11 
          LC  Mode  Stationary phase    Mobile phase      Principle  
Normal phase 
Chromatography 
Silica gel n-Hexane/Isopropyl 
alcohol 
Adsorption 
Reverse phase 
Chromatography 
Silica C18(ODS) Methanol/water Partition 
Sizeexclusion 
chromatography 
Porous polymer THF Gel 
permeation 
Ion-exchange 
chromatography 
Ion exchange gel Buffer solution Ion exchange 
Affinity 
chromatography 
Packing with 
ligand 
Buffer solution Affinity 
 
Normal Phase Chromatography:
12
 
Normal phase chromatography is a chromatographic technique that uses organic 
solvents as mobile phase and a polar stationary phase. Here the less polar components 
elute faster than the more polar components. Although it is described as “normal” it is 
not the most commonly used form of HPLC. The column is filled with tiny silica 
particles and is non- polar. A typical column has an internal diameter of 4.6mm. polar 
compounds in the mixture being passed through the column will stick longer to the 
polar silica than non-polar compounds. The non-polar ones will therefore pass more 
quickly through the column. 
 
Reversed —Phase Chromatography: 
RP-HPLC method is most commonly used in the pharmaceutical analysis as the 
compounds elute faster with high resolution. UV detection is the most common 
detection technique. Reverse phase chromatography, a bonded phase chromatography 
technique, uses water as the base solvent. Separation based on solvent strength and 
selectivity also may affected by column temperature and pH. In general the more 
polar components elute faster than less polar components. 
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Chromatogram 
All serous steps in method development will be summarized and a sequence of 
events that necessary to develop the method efficiently. The steps will be discussed 
in the same oder as they would be investigated during the method development 
process. The rational will be illustrated by focussing on developing a stability- 
indicating HPLC- UV method. The principles, however will be applicable to most 
other HPLC methods. High performance liquid chromatography is a convenient 
separation technique used for wide type of samples, due to its exceptional resolving 
power, speed and nano molecular detection levels. 
It is used in pharmaceutical research and development 
 To purify synthetic or natural products. 
 To characterize metabolites. 
 To assay active ingredients, impurities, degradation products and in 
dissolution. 
 In pharmacodynamics and pharmacokinetic studies. 
 
Analytical method validation: 
The validation of analytical procedures is an important part of the registration for 
application of a new drug
13-22
. The international conference on the Harmonization of 
technical requirements for registration of pharmaceutical for human used (ICH) has 
harmonised the requirements in two guidelines. Validation is a process of establishing 
documented evidence, which provides a high degree of assurance that a specific 
activity will consistently produce a desire result
23-24
. 
 
Method validation is a process of demonstrating that analytical procedures are 
suitable for their intended use and they support the identity, quality. Purity and 
potency of the drug substance and drug products. A successful validation guarantees 
that both the technical and regulatory objectives of the analytical method have been 
fulfilled. The real goal of validation process is to challenge the method and determine 
limits of allowed variability for the conditions needed to run the method
25-26
. 
 
Importance Method Validation 
The quality of analytical data is a key factor in the success of a drug development 
program. The process of method development and validation has a direct impact on 
the quality of these data
27
. 
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Analytical validation is a very important feature of any package of information 
submitted to international regulatory agencies in support of new product marketing or 
clinical trials applications. A thorough method development can almost rule out all 
potential problems, at the same time, a thorough validation program can address the 
most common ones and provide assurance for the intended purpose. In other words, a 
thorough validation can fulfil all the technical and regulatory objectives. A direct 
consequence and most significant outcome from any method validation exercise is 
the development of meaningful specifications, which can be predicted upon the use 
of validated analytical procedures that can assess changes in a drug substance or drug 
product during its life time. Analytical characteristics listed below may not be 
applicable to every test procedure or every particular material. It usually depends on 
the purpose for which the procedure is required; however, these aspects of validation 
should be given importance
28
. 
 
PARAMETERS OF ANALYTICAL METHOD VALIDATION 
1. Specificity: specificity is the ability of the method to accurately measure the 
analyte response in the presence of all potential sample components. The response in 
test mixtures containing the analyte and all potential sample components is compared 
with the response of a solution containing only the analyte. 
 
2. Accuracy: The accuracy of an analytical procedure expresses the closeness of 
agreement between the value, which is accepted either as a conventional true value or 
an accepted reference value and the value found. In a method with high accuracy, a 
sample is analyzed and the measured value should ideally be identical to the true 
value. Accuracy is represented and determined by recovery experiments. The 
standard range being 10% above or below the estimated range of claim. For assay 
methods, spiked samples are prepared in triplicate at three levels across a range of 
50-150% of the target concentration. The percent recovery should then be calculated.  
 
3. Precision: The precision of an analytical procedure expresses the closeness 
of agreement between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions.  
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Precision may be considered at three levels: 
 Repeatability 
 Intermediate precision  
 Reproducibility 
 
3.1. Repeatability: Repeatability expresses the precision under the same 
operating conditions over a short interval of time. Repeatability is also termed 
intra-assay precision. 
 
3.2. Intermediate precision: Intermediate precision expresses within-
laboratories variations: different days, different analysts, different equipment, 
etc. 
 
3.3. Reproducibility: Reproducibility expresses the precision between 
laboratories (collaborative studies, usually applied for standardization of 
methodology). 
 
4. Limits of detection and quantification: The limit of detection (LOD) is 
defined as the lowest concentration of an analyte in a sample that can be 
detected, not quantified. It is expressed as a concentration at a specified signal: 
noise ratio, usually 3:1. The limit of quantization (LOQ) is defined as the 
lowest concentration of an analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated operational conditions of 
the method. The ICH has recommended a signal: noise ratio 10:1. LOD and 
LOQ may also be calculated based on the Standard deviation of the response 
(SD) and the slope of the calibration curve(s) at levels approximating the LOD 
according to the formulae. The limit of detection (LOD) and limit of 
quantization (LOQ) may be expressed as: 
                         LOD =3.3 a/S  
            LOQ=10 a/S 
                     Where a = the standard deviation of the response 
                                  S = the slope of the calibration curve 
 
5. Linearity: Linearity of an analytical procedure is its ability to obtain test result 
which is directly proportional to the concentration of the analyte in the sample. 
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6) Range: The range of the analytical procedure is the interval between the upper and 
lower concentration of the analyte in the sample for which it has been demonstrated 
that the analytical procedure has a suitable level of precision, accuracy and linearity. 
 
 7. Robustness: Robustness measures the capacity of an analytical method to remain 
unaffected by small but deliberate variations in method parameters. It also provides 
some indication of the reliability of an analytical method during normal usage. 
Parameters that should be investigated are percent organic content in the mobile 
phase, pH of the mobile phase, buffer concentration, temperature, and injection 
volume. These parameters may be evaluated one factor at a time or simultaneously as 
part of a factorial experiment
29, 30
. 
 
8. Ruggedness: It involves analyzing the same sample under same experimental 
conditions by different analysts to check reproducibility of the method
31
. 
 
9. System suitability: System suitability of method was performed by calculating 
the chromatographic parameters like column efficiency, resolution, and asymmetric 
factor on the repetitive injection of standard solution
32
. 
 
Stability studies 
33, 34
 
The stability studies give an evidence for the variation of quality of drug product 
under the influence of various environmental factors such as temperature, humidity 
and light. The international conference of harmonization (ICH) has developed the 
guideline for stability of new drug substance and product. This guideline gives an idea 
about the stability data package required for registration. 
 
Main aim of carrying out the stability studies was to determine the re-test of the drug 
substance, establishing the shelf life of the drug products and recommending the 
proper storage condition of the drug product for long term storage and use. As a 
whole the stability studies are very much essential because the physical, chemical and 
microbial variation may cause a high degree of impact on the efficiency and security 
of the final drug product. 
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New dosage forms 
A new dosage form is defined as a medicinal product which contains the same active 
substance but in the form of different pharmaceutical product type as included in an 
existing product approved by the regulatory authority. This product may include 
product of new delivery system, various administration route, and different dosage 
form of same route of administration. The protocol for the new dosage forms stability 
studies may follow principles in the parent stability guideline. Mainly these studies 
include 6 months accelerated and 6 month long term data studies under the influence 
of various environmental factors.  
 
Parameters for stability study 
The international conference of harmonization has recommended various parameters 
for the stability testing of different pharmaceuticals. Mainly the parameters can be 
classified into three categories like physical, chemical, and microbiological. 
 
Physical parameters: The physical changes may be important criteria for stability 
testing. Mainly appearance, melting point, clarity and colour of the solution, moisture 
content or water content and particle size are checked and reported. All these factors 
must be under the acceptance range.   
 
Chemical parameters: This is one of the important areas where more concentration 
has to be taken in the time of stability testing. The determination of degradation 
products and the potency of the drug must be calculated by assay. Since these factors 
can affect the efficiency of the drug product proper testing must be required in this 
case. 
 
Microbiological parameter: As because the drugs have to be indented for long term 
storage chances of growth of micro-organism are high. So proper testing must be done 
for verifying any microbial changes taking place as due to various environmental 
factors. 
 
Batch selection: 
For both the bulk drug and drug dosage form stability studies must be carried out on 
at least three batches with a minimum of 6 month duration for both accelerated and 
long term testing. Manufacturing of the drug substance must be done for pilot scale in 
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the same route and method of manufacturing that was done on a manufacturing scale. 
For the drug product, two of the tree product must be pilot scale, and the third may be 
smaller. The batches taken must processes should be similar to the marketed drug 
product manufacturing procedure and quality specification. 
 
Storage condition: 
The storage condition for the stability studies was developed by ICH and it was 
mainly based on four geographic regions or climate zones. The world geographical 
region was defined by four climatic zones I – IV. Long term testing for the drug 
product is normally for every 3 month for the first year, and for 6 month for every 6 
month over the second year and then annually. For the accelerated testing for the 
drug product is normally for 1 month, 3 months and 6 months. A significant change 
in the stability for drug product is when the substance no longer meets the 
specification. For a drug product a significant change is considered when a 5 % 
change in potency, pH exceeds the limit, failure in dissolution limit and failure in 
physical attributes. For 12 month long term data drugs must be stored at a condition 
of 25
0
 C /60%RH and for 6 month accelerated study drugs must be stored at a 
condition of 40
0
C/75%RH. 
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CHAPTER 2 
LITERATURE REVIEW 
 
Nageswara Roa et al (2003) had reported a simple high performance liquid 
chromatographic method for the separation and estimation of synthetic impurities of 
norfloxacin in pharmaceutical dosage form. The developed method was used for the 
determination of chemical reactions during the development process an in the quality 
assurance department. Separation by the developed method was carried out by using a 
C18 column and the mobile phase used was 0.01M potassium dihydrogen 
orthophosphate and Acetonitrile at a ratio 60:40, v/v at pH 3.0.The detection 
wavelength was 260 nm diode array detector and the determination was done under 
isocratic condition at flow rate of 1.0ml/min. The developed method was found to be 
specific and precise for the estimation of raw material, intermediates and finished 
formulation of norfloxacin
35
. 
 
Breda Simonovska et al (1999) had evaluated and developed a high-performance 
thin-layer chromatography (HPTLC) method with direct fluorescence measurement 
for the estimation of norfloxacin. The validation of the developed method was carried 
out at a limit of 10 mg of norfloxacin per square meter on a stainless steel surface. 
Further modification of the method can be done at lower detection limit of about 5 ng 
norfloxacin. Comparison of the test solution were done between the developed high 
performance thin-layer chromatographic and the known HPLC method. Linearity, 
accuracy, precision were determined for the developed HPTLC method by 
densitometer or video system and was found to be almost comparable with the known 
HPLC method
36
. 
 
Kowalski et al (2005) developed a high performance liquid chromatography for the 
determination of norfloxacin from chicken tissues taken from different parts like liver, 
muscles and fat. The superannuated collected from tissue homogenate by 
centrifugation was used as the test sample. The analysis of the sample was done by 
using a reverse-phase C-18 column. The detection was done by using a fluorescence 
detector at 278 nm and 456 nm as excitation wavelength and emission wavelength 
respectively. The mobile phase used for the analysis was water: methanol at a ratio of 
Literature Review 
Dept. of Pharmaceutical Analysis, KMCH College of Pharmacy  Page 14 
 
65:35v/v at a pH 3 adjusted with phosphoric acid, which contain tetrabutyl 
ammonium hydrogen sulphate as ion‐pairing agent. The isocratic condition was 
carried out at a flow rate of 1ml/min. the limit of detection of norfloxacin in chicken 
tissues was found to be 2.5 ng/ml
37
. 
 
Fawas et al (1996) had carried out a high performance liquid chromatography for the 
determination of bioavailability of norfloxacin from PEG 6000 solid dispersion and 
cyclodextrin inclusion complexes in rabbits. The study was done in pure form of 
norfloxacin and its pharmaceutical formulation in various solvents form. The 
concentration of norfloxacin rabbit plasma was analysed by HPLC method with 
fluorimetric detection. The separation of the sample was achieved by using a 
Nucleosil C-18 column. The eluent used was a mixture of dihydrogenpotassium 
phosphate: methanol: Acetonitrile at ratio of 78:13:9 at Ph 3 adjusted with ortho-
phosphoric acid. The flow rate set for the determination was 1.6 ml/min and the 
detection was carried out at 380 and 450 nm as excitation and emission wavelength 
respectively. From the data’s obtained from the plasma concentration profiles it was 
found that the absorption of norfloxacin from SD and inclusion complexes is higher 
as compared with pure drug
38
. 
 
Bedore et al (2007) had developed a validated high performance liquid 
chromatography method with ultraviolet detection for norfloxacin from human 
plasma and application of the developed method for the bioequivalence study of two 
norfloxacin formulations. Ciprofloxacin was used as the internal standard for the 
study. Liquid-liquid extraction method was used for the extraction of norfloxacin and 
the internal standards from human plasma. Separation of norfloxacin, internal 
standard and plasma interferent were done by using a C-18 column with a mixture of 
20mM sodium hydrogen phosphate buffer (pH 3.0) and Acetonitrile with a ratio of 
88:12 v/v. The detection was carried out at a wavelength of 280 nm. The developed 
method was found to be linear from a range 25-3000 ng/ml. the recovery study and 
precision was performed and observed within the acceptable limits
39. 
Nafisur Rahman et al (2004) had reported a kinetic spectrometric method for the 
determination of norfloxacin in pharmaceutical dosage form. The development was 
done based on the oxidation of norfloxacin by alkaline potassium permanganate. The 
rate of change of absorbance is measured at 603 nm spectroscopically.  The 
Literature Review 
Dept. of Pharmaceutical Analysis, KMCH College of Pharmacy  Page 15 
 
calibration graph was made for determining the concentration of the drug by fixed 
time method. The linearity was observed at a range of 2.0 to 20 mg/ml. the obtained 
results are statically validated through recovery studies. The developed method was 
used for the estimation of norfloxacin in pharmaceutical dosage forms. The result 
finally obtained shows good accuracy and precision
40
.
 
Ibrahim et al (2009) have developed a simple spectroscopic validated method for the 
estimation of norfloxacin in pharmaceutical dosage form. The coloured product 
formed was measured spectroscopically at a wavelength of 625 nm. The different 
factors affecting the reaction was observed and recorded. The reaction pathway was 
postulated. Calculation of the activation energy of reaction was calculated and it’s 
found to be 5.072 kj/mol. The calibration curve was carried out by initial rate and 
fixed time method, and the graph were constructed at arrange of 20-150 and the limit 
of detection was found to be 8.4 and 3.2 gm/ml for initial rate and fixed method 
respectively. There was no interference observed from the excipients commonly 
found in the pharmaceutical dosage form. Interferences were observed from the 
excipients that are commonly present in the pharmaceutical formulations. The 
developed methods were totally validated and the results were found satisfactory. The 
developed method was successfully applied for the estimation of the norfloxacin in 
pharmaceutical dosage form
41
.
 
Johnson et al (2001) used a high performance liquid chromatography method for the 
stability study of norfloxacin oral syrup at room temperature under refrigerated 
condition for 56 days. a waters HPLC instrument with absorbance detector and a 
variable volume injector. The stationary phased used was spherisorb phenyl column 
and separation was done by using a eluent as a mixture of monobasic potassium 
phosphate buffer, Acetonitrile, methanol and trifluroacetic acid at ratio of 80:15:5:0.3. 
The flow rate was 1.0 ml and UV detection was done at 278 nm. The stability-
indicating method was done by using a sample of norfloxacin under heat, light and 
pH. The calibration curve was plotted between a range from 4.0 to 6.0 µg/ml. the 
correlation coefficient was found to be larger than 0.999. The precision was found to 
be satisfactory
42
.
 
Al deeb et al (1995) had developed a HPLC method for the estimation for the 
norfloxacin in bulk form in tablets. A shimadzu liquid chromatography was used with 
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a UV detector and reodyne injector.  The mobile phase used for the separation of 
norfloxacin was Acetonitrile, terebutyl ammonium hydroxide, phosphoric acid and 
water, with a flow rate of 2 ml/min and the detection was done at wavelength of 278 
nm. The stability indicating method was done by accelerated photolysis
43
. 
Ivana et al (2008) had developed a RP-HPLC method for the quantitative estimation 
of loperamide from its acid degradation product. The separation from degradation 
product was achieved by using a c-18 column. The eluent used for the separation of 
loperamide from its degradation product was sodium-octansulphonate, triethyl amine 
and ammonium hydroxide in water: Acetonitrile at a ratio of 45:55. The pH of the 
eluent was adjusted to 3.2 with phosphoric acid. The linearity graph was plotted 
between a range of 10-100 µg/cm. the developed method was applied for the 
determination of the marketed pharmaceutical formulation. The degradation of 
loperamide was done by using hydrochloride acid solution at different temperature
44
. 
Streel et al (2004) had developed a liquid chromatography-tandem mass spectrometry 
for the analysis of loperamide in human plasma. The sample was separated by using 
methanol and ammonium acetate solution as mobile phase. A LC-MS/MS system 
with atmospheric pressure chemical ionization is used for the analysis of loperamide. 
The quantitation limit was found to be 50 ng/ml and further validation was also done 
for the newly developed method like recovery, precision, trueness, accuracy and 
linearity
45
. 
Maycock et al (2000) had developed a liquid chromatographic method for the 
estimation of loperamide in rat plasma and bovine serum solutions. The rat plasma 
solutions were treated with meta phosphoric acid with a intention of protein 
precipitation. The supernatant produced were used as the sample for analysis and 
were injected to a reverse phase C18 column and the detection was done by using a 
UV detector at a wavelength of 195 nm.  Isocratic condition was employed for the 
separation and the flow rate was set at 1 ml/min at by using Acetonitrile: 
diethylamide: sodium phosphate buffer (40:0.08:60v/v/v) with 22 minutes as elution 
time. The method shows linearity between a range of 0-3 mg/ ml and 0-1 mg/ml for 
bovine serum solution and rat plasma solution respectively. The validation of the 
developed method was done and finally it was found to be suitable for the 
determination of bovine serum solution and rat plasma solution
46
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El Sherif et al (2000) had developed a two Spectrophotometric determination of 
loperamide in the presences of degradation products. The first method was based on 
ion-pair association complex formation by using different dyes like bromothymol 
blue, bromophenyl blue and naphtol blue black. Chloroform was used for the 
extraction of colored product and spectrophotometrically at 414, 415 and 627 nm for 
bromothymol blue, bromophenyl blue and naphtol blue black respectively. The 
method was found good for the analysis of loperamide degradation product. The 
developed second method was based between reactions of loperamide with iodine in 
chloroform. Linearity was observer at a range of 2.5–17.5 and 2.5–22.5 mg/ ml at 295 
and 363 nm, respectively. The developed methods have been used for the analysis of 
the drug in pure form and in its pharmaceutical formulation
47
. 
Alastair et al (2000) had developed and reported a liquid chromatography- mass 
spectroscopy method for the determination of loperamide and its N- dimethyl 
metabolite in human plasma.  Internal standard in the assay was O-Acetyl-loperamide. 
The samples were extracted with methyl tert.-butyl ether and the separation was 
achieved by a C18 as column and Acetonitrile –water containing 20nM ammonium 
acetate. No interfering peaks were detected at the time of separation by HPLC 
methods. Samples were analysed by using electro spray ionization in a triple 
quadrupole mass spectrometer. The method was satisfactorily validated
48
. 
 
Mahmoud et al (2011) had reported a RP-HPLC method for the simultaneous 
determination of tinidazole and norfloxacin in pharmaceutical tablet dosage form in 
the presence of some impurity. An isocratic condition was followed for the separation 
and the stationary phase used RP-18 column using the eluent methanol: 0.025M 
KH2PO4 with pH 3 adjusted with ortho-phosphoric acid. The flow rate was set at 4 
ml/min and the detection wavelength was 290 nm. The linear calibration curve was 
constructed between a range of 1-80 μg/mL for two drugs. The method was 
satisfactorily validated as per ICH guideline, the newly developed method was found 
to be accurate and was successfully used for the estimation of norfloxacin and 
tinidazole in its dosage form
49
. 
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Wang Jindong et al (1999) had developed a high performance liquid 
chromatography for the simultaneous estimation of norfloxacin and trimethorpimum. 
The method was developed by using a Zorbax ODS column as stationary phase and 
the separation was achieved by using eluent containing water: Acetonitrile: 
triethylamine at a ratio of 325:175:2 at pH 3.0 adjusted with phosphoric acid. The 
detection was carried out by using a UV detector at a wavelength of 240 nm and the 
flow rate was set at 1.0 ml/min. the linearity was observed between a range of 100-
300 and 25-75 mg/L for norfloxacin and trimethopriumum respectively. The 
developed method was validated and found to be simple, sensitive and stable
50
. 
Argekar et al (2006) had reported a RP-HPLC method for the determination of 
norfloxacin and tinidazole in tablet dosage form. The method was developed by using 
a C-18 column as stationary phase and 0.2 % Triethylamine in water: Acetonitrile at a 
ratio of 80:20 with pH 2.6 to 2.8 adjusted with Phosphoric acid. The detector 
wavelength was set at 311 nm with a flow rate of 1 ml/min. the linearity was found to 
be in the range of 20-200μg/mL and 30 - 300 μg/mL for norfloxacin and tinidazole 
respectively
51
. 
Reddy et al (1999) had reported a simultaneous determination method for norfloxacin 
and tinidazole in pharmaceutical formulation by derivative Spectrophotometric and 
graphical absorbance ratio method. It was found that norfloxacin and tinidazole has an 
maximum absorbance at 275 and 317.8 nm respectively. The absorbance of 
norfloxacin was measured at 264.2 and for tinidazole at 306.2 nm which are the zero 
crossing point of tinidazole and norfloxacin respectively in derivative 
spectrophotometry. The linearity was observed at arrange of of 0-24 µg/ml for 
norfloxacin and 0-36 µg/ml for tinidazole. In the case of graphical absorbance ratio 
method the Absorbance was measured at 275 nm and 300.4 nm for each drug and the 
Beer's law is obeyed in the concentration range of 0-20 µg/ml for both drugs. The 
developed methods were validated and were found to be satisfactory
52
. 
Pinak Patel et al (1999) had developed a validated high performance liquid 
chromatography method for the simultaneous determination of norfloxacin and 
ornidazole. The method was developed by using a PRONTOSIL AQ ODS coloumn. 
Isocratic condition was carried out by using 50mM Sodium dihydrogen phosphate 
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buffer: ACN: Methanol at pH 2.5 adjusted  with orthophosphoric acid. The elution 
rate was set at 1ml/min with a run time of 10 min and the detection was done at 294 
nm. The developed method was found to be linear at arrange of 4-20 μg/ml and 5-25 
μg/ml for norfloxacin and ornidazole respectively. The method was found to be 
accurate, precise and specific. The developed method was applied successfully for the 
simultaneous determination of norfloxacin and ornidazole in combined formulation
53
. 
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CHAPTER 3 
AIM AND OBJECTIVE 
The number of drugs and drug formulations introduced into the market by 
pharmaceutical industries is rising at an alarming pace. These drugs and formulations 
may be either novel entities or partial modifications of the existing ones or they may 
be multi component dosage forms. The complexity of the dosage form posses’ 
significant challenge to the analytical chemist during the development of assay 
methods. 
Development of newer analytical procedures for the evaluation of drugs and their 
formulation is necessary for the following reasons. 
1) The drug or drug combinations may not be official in pharmacopoeia. 
2) A literature survey may not reveal any analytical procedure for the drug or its 
combinations. 
3) Analytical methods for the quantification of the drug or its combination from 
biological fluids may not be available. 
4) Newer methods are also suggested when the existing method are expensive, 
problematic and are not dependable and adequately sensitive. 
The formulation consisting of Loperamide hydrochloride and Norfloxacin in 
combination is used in the treatment of diarrhea. For the determination of norfloxacin 
HPLC
35
, HPTLC
36
 and Spectroscopic method
40, 41 
and for the determination of 
loperamide HPLC
44
, LC-MS
45
, Spectroscopic method
47
 had been already reported. 
But there is no analytical method for the analysis of these compounds in combination; 
hence an attempt was made to estimate these two drugs by RP-HPLC. 
Hence primary objective of the work envisaged was to 
1) Develop an analytical method for the simultaneous estimation of Loperamide 
hydrochloride and Norfloxacin in combination. 
2) Validate the method as per ICH guidelines. 
3) Determination of stability of the formulation by developed and validated assay 
method. 
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CHAPTER 4 
DRUG PROFILE 
 
 Drug Name                             :  Loperamide hydrochloride 54 
 Molecular formulae    :  C29H33ClN202.HCl 
 Molecular weight        :  513.5 g 
 Chemical structure 
 
Fig 2. Structure of Loperamide hydrochloride 
 
 IUPAC Name      : 4-[4-(4-chlorophenyl)-4hydroxypiperidin-1- 
                                                                    yl]-N,N-dimethyl-2,2-diphenlybutamide  
                                                                    Hydrochloride    
 Appearance     :  White or almost white powder 
 Solubility                :  Slightly soluble in water, freely soluble in    
                                                 Alcohol and in methanol 
  Melting point        :  228˚C 
 Storage      :  Protected from light 
 Loss on drying         : Not more than 0.5% determined on 1.0 g  
by drying in an oven at 105˚C for 4 hour 
 Sulphated ash    : Not more than 0.1% determined on 1.0 g 
  Category    : Long-acting synthetic ant diarrheal agent 
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 Drug Name                             :  Norfloxacin 55 
 Molecular formulae    :  C16H18FN3O3 
 Molecular weight        :  319.3 g 
 
 Chemical structure  
 
                                                Fig 3. Structure of Norfloxacin 
 
 
 IUPAC Name      : 1-Ethyl-6-fluro-4-oxo7-(piperazine-1-yl)-  
                                                              1,4- Dihydroquinoline-3-carboxylic acid. 
                                                               
 Appearance     :  White or pale yellow, hygroscopic, 
                                                   photosensitive, crystalline powder. 
 Solubility                :  Very Slightly soluble in water,   
                                                   Slightly soluble in Acetone and alcohol 
                                                   and in methanol 
 Melting point        :  227-228˚C 
 Storage      :  In an airtight container, protected from  
light. 
 Loss on drying         :         Not more than 1.0% determined on 1.0g  
by drying in an oven at 105˚C for 2 
hours. 
 Sulphated ash    : Not more than 0.1% determined on 1.0 g. 
  Category    :  Anti-Infective 
                                                              Anti-Bacterial Agents 
                                                              Enzyme Inhibitors 
                                                              Nucleic Acid Synthesis Inhibitors 
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CHAPTER 5 
MATERIALS AND METHODS 
6.1 Drug samples:  
Norfloxacin and Loperamide HCl and are procured from Wockhardt Ltd (India) 
where the potency of Loperamide hydrochloride and Norfloxacin was reported to be 
99.3% w/w and 99.7% w/w respectively. 
 
6.2 Chemicals and Solvents Used: 
 Acetonitrile HPLC grade      –  Merck specialties 
 Methanol (Analytical and HPLC grade)            –  Merck specialties 
 Ortho phosphoric acid (Analytical grade)    –         Merck specialties 
 Triethylamine (Analytical grade)                                     _         Merck specialties 
 Water (HPLC grade)        –  SD fine chemicals 
 
6.3 Instruments:  
 HPLC    :  Waters HPLC 2695 separation module with Empower 
software 
 UV        :  PerkinElmer 
 Sonicator  :  Elico ultra sonicator (Sensitivity 0.0001 g) 
 Weighing balance :  Mettler Toledo 
 pH meter  :  Lab India  
 Solvent filtration  :  Millipore 
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6.4 METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITION: 
 
6.4.1 Selection of wavelength:  
The wavelength for the estimation of loperamide hydrochloride and norfloxacin was 
selected by injecting several times of mixed standards10 µg/ml each of both the 
drugs. The standard solution was scanned between 200-400nm. UV spectrum of both 
drugs shows good absorption in range between 210 – 240 nm. Hence 222 nm was 
selected as the detection wavelength.  
 
6.4.2 Selection of method for separation: 
Proper selection of the method depends upon the nature of the sample, its molecular 
weight and solubility. The drugs selected in the present study are polar in nature and 
hence RP-HPLC method was selected for the initial separation because of its 
simplicity and suitability. 
 
6.4.3 Selection of Chromatographic condition: 
Initial Chromatographic conditions 
 Equipment System       :   WATERS 2695 SEPERATION MODULE  
 Detector        :   Photo Diode array  
 Injector          :  Rheodyne 
Stationary phase    :  Phenomenex C18 (250×4.6 mm, 5 µm) 
  
The optimization of HPLC parameters was done by investigating the influence of the 
mobile phase composition while stationary phase, detection wavelength, injection 
volume and column temperature were set constant.  
 
Chromatographic conditions-1       
Stationary phase  :          Phenomenex C18 (250×4.6 mm, 5 µm)        
Mobile Phase                          :          Water                    
Elution type                 :          Isocratic  
Solvent ratio   :          100% 
 Detection   :  222 nm 
 Flow rate   :  1 ml/min 
 Sample size   :  20 µL 
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 Needle wash   :  Extended 
Column temperature  :  40 
 
Chromatographic conditions-2 
Stationary phase  :           Phenomenex C18 (250×4.6 mm, 5 µm)         
Mobile Phase               :           Methanol                   
Elution type                 :           Isocratic  
Solvent ratio   :   100% 
 Detection   :  222 nm 
 Flow rate   :  1 ml/min 
 Sample size   :  20 µL 
 Needle wash   :  Extended 
 Column temperature  :  40 
 
Chromatographic conditions-3 
Stationary phase           :           Phenomenex C18 (250×4.6 mm, 5 µm)  
Mobile Phase                           :          ACN                   
Elution type                  :  Isocratic  
Solvent ratio   :   100% 
Detection   :  222 nm 
Flow rate   :  1 ml/min 
Sample size   :  20 µL 
Needle wash   :  Extended 
Column temperature  :  40 
 
Chromatographic conditions-4 
Stationary phase  :           Phenomenex C18 (250×4.6 mm, 5 µm)      
Mobile Phase               : ACN: Water                    
Elution type                  :       Isocratic  
Solvent ratio   :   1:1 
Detection   :  222 nm 
 Flow rate   :  1 ml/min 
 Sample size   :  20 µL 
Needle wash   :  Extended 
 Column temperature  :  40 
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Chromatographic conditions-5 
Stationary phase  :           Phenomenex C18 (250×4.6 mm, 5 µm)  
Mobile Phase                          :           ACN: Water: H3PO4  
                                         pH 4.5 (adjusted with triethylamine)                   
Elution type                            :           Isocratic  
Solvent ratio              :          50:50:0.2 v/v/v 
Detection   :          222 nm 
Flow rate   :          1 ml/min 
Sample size   :          20 µL 
Needle wash   :  Extended 
Column temperature  :  40 
 
At the initial chromatographic condition the developing method with different mobile 
phases was used (water, methanol, ACN, ACN: Water) but no favorable results were 
obtained. But the mobile phase consists of ACN: water: phosphoric acid ph 
4.5(adjusted with triethylamine) (50:40:10) give acceptable peak. Therefore for the 
present study ACN: water: phosphoric acid ph 4.5(adjusted with triethylamine was 
selected as the mobile phase. 
 
6.4.4 Effect of pH 
Keeping the ratio of mobile phase constant (50:50:0.2) ratio of ACN: water: 
phosphoric acid ph 4.5(adjusted with triethylamine) and the chromatogram was 
recorded at pH 3.5, 4.0, 4.5 with the flow rate of 1.0 ml/min. Peak merging and peak 
tailing was observed at 3.5 and 4.0 respectively. At 4.5 peaks with good resolution 
and symmetry was observed. Hence pH of 4.5 was selected for our study. 
 
6.4.5 Effect of flow rate 
Keeping the mobile phase ACN: water: phosphoric acid ph 4.5 (adjusted with 
triethylamine) the chromatogram was recorded at flow rate of 0.5, 1.0, 1.5 ml/min. 
But when using the flow rate of 0.5 and 1.5 ml/min no satisfactory results were found. 
At the flow rate of 1 ml/min the peaks were sharp with good resolution. Therefore for 
the present study 1 ml/min was selected as the flow rate. 
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6.4.6 Fixed chromatographic condition 
Stationary phase :           Phenomenex C18 (250×4.6 mm, 5µm)  
Mobile Phase              :           ACN: Water: H3PO4  
                             pH 4.5 (adjusted with triethylamine)                   
Elution type                :           Isocratic  
Solvent ratio  :   50:50:0.2 v/v/v 
Detection  :  222 nm 
Flow rate  :  1 ml/min 
Sample size  :  20 µL 
Needle wash  :  Extended 
Column temperature :  40 
 
6.5 Preparation of Standard stock solutions: 
6.5.1 Standard stock solution A: 
Accurately weighed 200 mg of Norfloxacin and transferred into a 100 ml volumetric 
flask, dissolved in 25 ml of mobile phase, sonicated for 5 min and the final volumes 
make up with mobile phase. 
 
6.5.2 Standard stock solution B: 
Accurately weighed 20 mg of Loperamide hydrochloride and transferred into a 100 
ml volumetric flask, dissolved in 25 ml of mobile phase, sonicated for 5 min and the 
final volumes made up with mobile phase. 
 
6.5.3 Preparation of working Standard solutions: 
Accurately pipette out 10 ml of standard stock solution A and 1 ml of standard stock 
solution B into a 100 ml volumetric flask, dissolved and make up to the final volume 
with mobile phase. 
 
6.5.4 Preparation of sample solution:   
Accurately weighed 210 mg of powdered sample and transferred into a 100 ml 
volumetric flask, dissolved with 25 ml of mobile phase, sonicated for 10 min and the 
final volume was made up with methanol and filtered through whatmann filter paper 
No: 41. The final mixed sample solution was prepared, corresponding to 200 µg/ml of 
norfloxacin and 2 µg/ml of Loperamide hydrochloride with the same solvent. 
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 6.6 HPLC Method Validation: 
After developing a method its validation is necessary to prove the suitability of the 
method for the intended purpose. The developed HPLC method was validated for 
accuracy, precision, linearity, robustness, limit of detection (LOD), limit of 
quantification (LOQ) and system suitability. The validation was carried out as per 
ICH guidelines (1996). The procedures followed for the validation of the method are 
given below. 
 
6.6.1 System suitability: 
System suitability determination was carried out by replicate analysis of the system 
suitability solution of both drugs. It was performed by calculating the 
chromatographic parameters like column efficiency, resolution, peak asymmetry 
factor etc.   
 
6.6.2Specificity: 
Specificity is the ability of an analytical method to differentiate and quantify the 
analyte in presence of other components in the sample. The specificity of the method 
was determined by complete separation of Loperamide and Norfloxacin with 
parameters like retention time (Rt), resolution (Rs) and tailing factor (T), peak purity.  
Peak purity of the method was evaluated by calculating the difference between peak 
angle (θp) and peak threshold angle (θth). If θp < θth, the peak is considered spectrally 
homogeneous; otherwise the peak is influenced by the presence (i.e., additional 
absorption) of another substance. Peak purity evaluation was performed with the 
objective to prove that the method is specific in nature. 
 
6.6.3 Linearity and Range (Calibration curve): 
A calibration curve was plotted over a concentration range of (5-25 µg/ml)                           
for both the drugs. The chromatogram of each solution was recorded at 222 nm. 
Calibration curve were constructed for LOP and NOR by plotting peak area versus 
concentration. Each reading was the average of five replicate injections. The linearity 
was assessed by calculating the slope, y-intercept and coefficient of determination 
(R
2
). 
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6.6.4 Precision: 
The precision of an analytical method is usually expressed as the standard deviation, 
relative standard deviation or coefficient of variation of variance of a series of 
measurement. It was examined by performing the intra-day and inter-day studies. 
Three replicate injections of the mixture of standard solution at five concentration 
levels (5, 10, 15 µg/ml) were carried out and the standard deviation and relative 
standard deviation was calculated. The intra-day studies was performed at intervals of 
3h in a day, while the inter day studies was performed over in alternative days. 
 
6.6.5 Accuracy: 
Determination of accuracy was done by calculating the recoveries by using standard 
addition method. Known amount of the standards (50, 100, 150 %) were added into 
the pre-analyzed sample solutions and the amount of these standard were estimated by 
using assay method. 
6.6.6 Robustness: 
The robustness of the method is to measure the ability of the method to remain 
unaffected by small variations in parameters of the method and there by provides an 
indication of its reliability during normal usage. The robustness of the proposed 
method was evaluated by changing the flow rate, column and pH. 
 
6.6.7 Ruggedness: 
It expresses the precision within laboratory variations like different days, different 
analyst, and different equipments. Ruggedness of the method was assessed by spiking 
the standard six times in two different days with different analyst. 
 
6.6.8 Limit of Detection (LOD): 
The detection limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantitated as an exact 
value. LOD of both the analytes were determined by k SD/b where k is a constant (3.3 
for LOD), SD is standard deviation of the analytical signal, and b is the slope of the 
concentration/response graph. 
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6.6.9 Limit of Quantification (LOQ): 
The quantification limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision 
and accuracy. The quantitation limit is a parameter of quantitative assays for low level 
of compounds in sample matrices and is used particularly for the determination of 
impurities or degradation products. LOQ of both the analytes were determined by k 
SD/b where k is a constant (10 for LOQ), SD is the standard deviation of the 
analytical signal, and b is the slope of the concentration/response graph. 
 
6.7 Accelerated stability study: 
The accelerated stability studies are done for the verification of quality of the drug 
under the influence of various environmental factors. The stability of the formulation 
was analyzed by performing the assay of the formulation by the developed RP-HPLC 
method. The samples are stored at 40
0
/70% and they were analyzed at 1, 2, 3 and 6 
months. 
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CHAPTER 6 
RESULTS 
Table 1.  System suitability parameters 
Parameters NOR   LOP 
Number of theoretical plates 80121 7543 
Asymmetry factor 0.97 1.09 
Resolution 2.44 
Limit of detection 1.17 0.16 
Limit of quantification 3.59 0.39 
Linearity range 5-25 µg/ml 5-25 µg/ml  
                                                                  
Table 2. Linearity and range (n=5) 
 
 
 
 
 
 
 
                  
 
  
S.NO. Conc. of NOR 
(g/ml) 
Mean Peak area 
of NOR 
1 
2 
3 
4 
5 
5 
10 
15 
20 
25 
164936 
321621 
471238 
658712 
814816 
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Table 3. Linearity and range (n=5) 
 
 
 
 
 
 
 
 
 
 
Table 4. Recovery data for the proposed method 
 
Drug 
Quantity 
added % 
Quantity 
found, 
mg/ml 
Recovery, % %RSD 
NOR 
50 99.48 99.46 0.84 
100 200.02 100.13 0.69 
150 299.97 99.85 1.26 
LOP 
50 0.97 99.94 0.64 
100 2.01 100.05 0.77 
150 3.19 100.76 0.41 
 
     
 
 
S.NO. Conc. of LOP 
(g/ml) 
Mean Peak area of 
LOP 
1 
2 
3 
4 
5 
5 
10 
15 
20 
25 
122618 
239261 
370322 
494158 
596517 
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Table 5. Intraday assay precision data (n=3) 
       
Table 6. Interday assay precision data (n=3) 
 
 
 
 
 
Concentration 
(µg/ml) 
Intraday 
Peak area Peak area 
Mean %RSD Mean %RSD* 
 NOR LOP 
5 µg/ml 165494 1.106 121817 0.572 
10 µg/ml 322867 0.338 242747 0.474 
15 µg/ml 487606 0.319 368093 0.277 
Day 
 
 
Concentration 
 
Interday 
Peak area Peak area 
Mean area %RSD Mean %RSD* 
NOR LOP 
Day 1 5 µg/ml 165494 1.106 121817 0.572 
10 µg/ml 322867    0.338 2427467 0.474 
15 µg/ml 487606 0.319 368093 0.277 
Day2 5 µg/ml 163972 0.817 120964 0.621 
10 µg/ml 323452 0.512 241961 0.371 
15 µg/ml 489213 0.456 367919 0.466 
Day3 5 µg/ml 164764 0.931 122176 0.361 
       10 µg/ml 326109 0.792 241635 0.217 
       15 µg/ml 483946 0.521 370264 0.839 
Results 
Dept. of Pharmaceutical Analysis, KMCH College of Pharmacy  Page 34 
 
 
Table 7. Robustness testing of the method 
 
     
Table 8. Analysis of formulation 
 
Components 
Label claim 
mg/g 
Amount 
found 
mg/g 
% claim 
NOR 200 199.93 99.88 
LOP 2 2.05 100.14 
 
 
 
 
 
 
Parameters changed 
% Assay 
NOR LOP 
Column brand 
Phenomenex 99.66 99.29 
Hypersil 101.12 98.63 
Waters 98.69 99.82 
pH 
4.3 98.88 99.17 
4.5 99.39 100.39 
4.7 98.18 98.85 
Flow rate 
0.9 ml/min 99.29 99.37 
1.0 ml/min 100.93 98.49 
1.1 ml/min 101.53 98.24 
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Table 9. Ruggedness testing of the method 
Drug 
 
 
Concentration 
( µg/ml ) 
Mean peak 
area 
% RSD 
NOR 
Day 1 
Analyst 1 
10 321621 0.348 
 
Day 2 
Analyst 2 
10 322119 0.721 
LOP 
Day 1 
Analyst 1 
10 239261 
0.624 
 
Day 2 
Analyst 2 
10 241174 0.297 
 
Table 10. Accelerated stability study 
 
ASSAY 
DRUGS 
0 month 1 month 2 month 3 month 6 month 
NOR 99.8% 99.4% 99.1% 98.7% 98.1% 
LOP 
100.1% 99.7% 99.3% 99.1% 98.5% 
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Fig 4. Calibration curve of Norfloxacin. 
 
 
 
Fig 5. Calibration curve of Loperamide. 
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Fig 6. Chromatogram for retention time of norfloxacin 
 
 
 
Fig 7.Chromatogram for retention time of loperamide 
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Fig 8. Chromatogram of Linearity Standard solution of NOR and LOP 5 µg/ml 
 
 
 
Fig 9. Chromatogram of Linearity Standard solution of NOR and LOP 10 µg/ml 
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Fig 10. Chromatogram of Linearity Standard solution of NOR and  
LOP 15 µg/ml 
 
Fig 11. Chromatogram of Linearity Standard solution of NOR and  
LOP 20 µg/ml 
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Fig 12. Chromatogram of Linearity Standard solution of NOR and 
 LOP 25 µg/ml 
 
Fig 13. Chromatogram of sample solution of NOR and LOP 
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Fig 14. Chromatogram of sample Peak profile of Norfloxacin 
 
Fig 15. Chromatogram of sample Peak profile of Loperamide 
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CHAPTER 7 
DISCUSSION 
 
Combination of Loperamide and Norfloxacin is used as an anti-diarrheal agent. From 
the literature survey it was found that no method has been reported for the 
simultaneous estimation of LOP and NOR in combination. Hence a validated RP-
HPLC method has been developed for the simultaneous estimation of these drugs in 
combined form. 
 
Optimization of chromatographic conditions 
Suitable selection of the method depends upon the nature of the sample, its molecular 
weight and solubility. Hence the drugs selected in the present study are polar in 
nature, RP-HPLC method was selected for the initial separation because of its 
simplicity and suitability. The method was performed on a Phenomenex C18 
(250×4.6 mm, 5 µm) column. 
 
For the determination of wavelength for the simultaneous estimation of LOP and 
NOR an UV overlay spectrum was recorded in the range of 200-400 nm and both 
drugs shows a good absorption in the range between 210 and 230 nm. Hence 222 nm 
was selected as wavelength of detection.   
 
The optimization of HPLC parameters was done by investigating the influence of the 
mobile phase composition while stationary phase, detection wavelength, injection 
volume and column temperature were set constant.  
 
In the case of 1st chromatographic Conditions water was selected as mobile phase at a 
ratio of 100% but resulted in poor elution of peaks. Hence methanol was selected 
instead of water at a ratio of 100% and chromatograms were recorded in Conditions 2. 
While using methanol as the mobile phase, peak merging was observed. As a result 
ACN was selected as mobile phase at a ratio of 100% in condition 3.In this peak 
resolution was obtained but the peak symmetry was not good and not within the 
acceptance criteria. Therefore, ACN: Water: H3PO4 was selected for the condition 4 
as mobile phase and peaks with poor resolution were obtained.  So in condition 5 the 
pH of the above mobile phase was adjusted to 4.5 with triethylamine. Finally in the 
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chromatographic condition 5 the peaks with good resolution and peak symmetry were 
observed and therefore this was selected as the mobile phase system for the 
determination of the drugs.  
 
Method validation 
The method developed for the determination of loperamide hydrochloride and 
norfloxacin in combined dosage form was validated for accuracy, precision, linearity, 
robustness, ruggedness, system suitability, LOD and LOQ. The validation was carried 
out as per ICH guidelines. 
 
System suitability 
Five duplicate injections of the system suitability solution gave %RSD value for peak 
area within 2%, indicating low difference of the calculated values (Table 1). The 
symmetry of all peaks was < 2. The resolution (R) between Loperamide and 
Norfloxacin was 5.11, representing a high degree of peak separation (R>2). The 
efficiency of the column, as uttered by the number of theoretical plates, was more 
than 2000. These results revealed the suitability of the HPLC system and conditions 
of the developed method. 
 
Specificity  
Specificity determination was done by analyzing loperamide hydrochloride and 
norfloxacin simultaneously.  Peaks for the drugs were observed to be well separated 
and not interfered with any other components. Peak threshold angle (θth) of all the 
peaks was found to be larger than that of peak angle (θp), values are shown in Figures 
(h,i)  indicating the purity of the peaks.  
 
Calibration curve (Linearity) 
Five working solutions each for loperamide and norfloxacin in the range of 5-25 
µg/ml were prepared respectively. Multiplicative of each solutions were injected and 
the linear regressions analysis of NOR and LOP were constructed by plotting the peak 
area of the analytes (y) versus analyte concentration (µg /ml) on (x) axis. The slopes, 
y-intercepts and correlation coefficients (R
2
) obtained from regression analysis are 
shown in (Table 2, 3, Figure 11, 12). The regression equation were y = 32737x - 4790 
(R
2 
=0.9989), y = 24054x + 3766 (R
2 
=0.9985) for NOR and LOP respectively. Linear 
regression analysis revealed that the R
2
 values for both the drugs were >0.999 
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confirming the linear relationship between the concentration of the analytes and area 
under the curve.  
 
Precision 
The intra-day precision was evaluated by analyzing five replicate samples of each at 
three different level (5, 10, and 15) containing pure drug. The % RSD value revealed 
high precision of the developed method. The inter-day precision was evaluated by 
analyzing five replicate samples of each at three different level (5, 10, and 15) 
containing pure drug. The % RSD value revealed high precision of the developed 
method.   
 
Accuracy 
The recovery of the investigated drugs ranged from 99.46-100.76%, and their %RSD 
values were all < 2% as shown in Table 4. It was identified from recovery tests that 
all percentage recoveries were within 99-101%, signifying the excellent accuracy of 
the developed method. 
 
Robustness 
As shown in Table 7 robustness data of the mean obtained (n=6) for each factor 
studied, including that the selected factors remained unaltered by small variations of 
these parameters. The individual recovery was obtained and the mean were between 
98-102% for both loperamide and norfloxacin. Thus the method was found to be 
robust for change in column manufacturer, pH and flow rate. 
 
Ruggedness 
According to ICH guidelines ruggedness was performed during the development of 
analytical procedure. By comparing inter-day and intraday precision result done by 
two analyst the ruggedness of the method can be assessed. The % RSD values were 
found to be less than 2 for intra-day and inter-day assay of Norfloxacin and 
Loperamide indicates the ruggedness of the method as shown in table 9.   
 
Limit of detection (LOQ) and Limit of quantification (LOD) 
The detection limit was found to be 1.17 for Norfloxacin, 0.16 µg/ml for Loperamide 
and the quantification limit was found to be 3.59 µg/ml for Norfloxacin and 0.39 
µg/ml for Loperamide. These results show that the method gives enough sensitivity. 
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Accelerated stability studies 
The content of NOR and LOP evaluated for the fabricated formulation after 
accelerated stability study at 40
0
C/75%RH for a period of 6 months. Assay values 
were found to be satisfactory (±10%) as compared to the label claim of the drugs as 
shown in Table 10.  
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CHAPTER 8 
SUMMARY AND CONCLUSION 
      SUMMARY 
 For the quantitative estimation of Norfloxacin and Loperamide HCl in 
combined capsule dosage form a RP-HPLC method was developed 
 The developed method was validated for different parameters like system 
suitability, specificity, linearity, accuracy, precision, LOD, LOQ, robustness 
and ruggedness. All these studies was carried out as per ICH guidelines 
 Form the developed method the retention time was found to be 2.09 and 4.51 
min for NOR and LOP respectively. 
 The developed method was found to be linear in the range of 5-25 µg/ml for 
both NOR and LOP. 
 The detection and quantification limits were found to be 1.17 and 3.59 µg/ml 
for NOR and 0.16 and 0.39 µg/ml for LOP respectively. 
 The recovery of the components ranged from and their %RSD values were 
found to be within the limit (< 2%). The precision result also revealed that the 
% RSD values of both NOR and LOP were less than 2%. 
 It was observed that the developed and validated method for the estimation of 
NOR and LOP was found to be robust and rugged. 
 The developed and validated method was successfully applied for the 
quantitative and qualitative estimation of NOR and LOP in combined capsule 
formulation. 
 The/ formulation containing NOR AND LOP was found to be stable after 
accelerated stability study performed at 40
0
c/75%RH for a period of 6 months.  
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CONCLUSION  
 
The developed validated RP-HPLC method was successfully applied for the routine 
simultaneous estimation of NOR and LOP in capsule dosage form and can be 
applicable for its stability studies. The method was cost effective due to low retention 
time (less than 5 min for both drugs) and less consumption of mobile phase. No 
interferences of excipients were observed in the sample chromatogram. The 
developed method can be applicable for the routine analysis of these drugs in 
pharmaceutical formulation.  
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